Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GSK's ViiV Healthcare Gets EMA Committee's Recommendation to Expand Use of HIV Drugs

GSK's ViiV Healthcare Gets EMA Committee's Recommendation to Expand Use of HIV Drugs

MT newswireMT newswire2026/11/16 10:16
06:16 AM EST, 11/16/2026 (MT Newswires) -- GSK's (GSK) majority-owned ViiV Healthcare said Monday that a committee of the European Medicines Agency has recommended approval to expand the use of its HIV drugs Tivicay and Dovato in younger age groups, including eligible newborns. The Committee for Medicinal Products for Human Use recommended extending the use of Tivicay's dispersible tablets, in combination with other antiretroviral medicines, to treat HIV in adults, adolescents, children and newborns weighing at least 2 kilograms, ViiV said. The committee also recommended approval of Dovato's new dispersible tablet formulation for treating HIV-1 infection in children aged at least 3 months and weighing at least 6 kg but less than 25 kg. Additionally, it recommended expanding the use of Dovato's existing film-coated tablets to children weighing at least 20 kg, the company said. The European Commission's decision is expected in Q1 of 2027, the company said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!